WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

NewsGuard 100/100 Score

WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, and NuGEN Technologies, Inc., a leader in innovative genomic samples preparation, today announced they will co-develop and co-market simple, seamlessly integrated workflows for gene expression profiling and target enrichment to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens, such as formalin fixed paraffin embedded tissue (FFPE).

Under the collaborative relationship, the two companies will conduct joint product development projects to construct validated workflows with both NuGEN's proprietary sample preparation and isothermal linear amplification (SPIA®) products and the WaferGen SmartChip Real-Time PCR System. The projects will focus on solutions for sample preparation, preamplification, and nucleic acid detection for gene expression and target enrichment from various sample types to drive speed and simplicity.

"By combining the expertise of both companies, we can offer a simple and straightforward workflow solution for single cell analysis, archival tissues and next generation sequencing addressing the needs of customers with precious nucleic acid samples who wish to perform high-throughput, high-density real-time PCR," said Alnoor Shivji, Chairman and CEO of WaferGen.  "This will expand the market potential of our SmartChip System by offering ready-to-go applications for biomarker discovery, validation and screening."

"NuGEN's unique sample preparation solution integrated with WaferGen's SmartChip System is clearly synergistic," said Elizabeth Hutt, CEO of NuGEN Technologies.  "NuGEN's expertise in solving the challenges associated with clinical samples, such as formalin-fixed, paraffin-embedded tissues or fine needle aspirates, will be leveraged in a simple workflow from sample to analysis expediting disease research and clinical applications."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MIT researchers develop new method to quickly screen cancer-associated genetic mutations